Home / Aesthetics / Dermal filler consent: tear trough, lips and the risks you must record

Aesthetics consent

Dermal filler consent: tear trough, lips and the risks you must record

Dermal fillers are the most-claimed aesthetic treatment in the UK. Fillers are also where the rare-but-catastrophic risk lives. Consent that names those risks, and a record that proves it, is the difference between a claim that stalls and one that ends a clinic.

Why filler consent carries the most weight

Filler complications run from the common and cosmetic to the rare and devastating. Montgomery requires you to disclose the material risks a reasonable patient would want to know. For fillers, the most serious of those is vascular occlusion, and for the tear trough and other periocular sites, the possibility of blindness. A record that names those risks specifically is your strongest document.

The material risks to disclose and document

  • Bruising, swelling and tenderness, the common effects.
  • Lumps, nodules and the Tyndall effect (a bluish tinge in thin skin such as the tear trough).
  • Infection and delayed inflammatory reactions, which can appear weeks or months later.
  • Product migration and asymmetry.
  • Vascular occlusion: filler blocking a blood vessel, causing tissue ischaemia and, if untreated, necrosis. This is the emergency you consent for. Read the full guide.
  • Blindness from occlusion of a retinal artery, a recognised risk of periocular and tear-trough treatment. Rare, but material, and exactly what a claimant will say they were never warned about.

What the record must contain

Beyond the risk discussion, filler documentation should capture the product and batch or lot number, volume, and injection sites (an injection map), the consent to hyaluronidase including its own small risk of allergy and anaphylaxis, and pre-treatment photographs. When a letter of claim arrives eighteen months later, these are the entries that answer questions before they are asked.

Tear trough: the highest-stakes site

The tear trough sits over the anatomy where filler complications are most feared. It is also a treatment patients often request for a specific event or appearance, which makes the tailored, patient-centred discussion Montgomery demands especially important. Record why the tear trough was chosen or declined, the specific periocular risks explained, and the reflection time given.

Alternatives (McCulloch)

Reasonable alternatives to record include no treatment, skin boosters or skin quality treatments, and, where relevant, surgical options. In elective aesthetics, doing nothing is a reasonable alternative every time, and a record showing it was genuinely offered is one of the strongest defensive entries in the file.


Where this sits

Every material risk below is a Montgomery disclosure and, where an alternative exists, a McCulloch one too. If it was discussed, it needs to be on the record. See how the standard rose in the interactive timeline, and how a claim actually unfolds in Anatomy of a Claim.

Related: Vascular occlusion  ·  Botulinum toxin consent  ·  Blepharoplasty consent  ·  Aesthetics overview

Common questions

Questions clinicians ask.

Bruising, swelling, lumps and nodules, the Tyndall effect, infection, delayed inflammatory reactions, migration, and the serious risks of vascular occlusion and, for periocular or tear-trough treatment, blindness. Montgomery requires the material ones to be disclosed and the record to show they were, tailored to the patient.

Yes. Blindness from retinal artery occlusion is a recognised, material risk of periocular and tear-trough filler. It is rare but severe, which is precisely the kind of risk Montgomery says a reasonable patient would want to know. A record that names it specifically is essential.

The material-risk discussion tailored to the patient, the reasonable alternatives offered (including no treatment), consent to hyaluronidase and its risks, the product and batch or lot number, the volume and injection sites, pre-treatment photographs, and evidence of time to reflect.

Because disclosure demands it. If a product is recalled or a reaction is investigated, the batch or lot number, product and volume are part of a defensible record. Their absence is a gap a claimant solicitor will highlight.

Next step

Does your filler record name the risks that matter?

Readiness Score